| Title |
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, December 2015
|
| DOI | 10.2147/dddt.s93545 |
| Pubmed ID | |
| Authors |
Khiem A Tran, Michelle Y Cheng, Anupam Mitra, Hiromi Ogawa, Vivian Y Shi, Laura P Olney, April M Kloxin, Emanual Maverakis |
| Abstract |
The treatment of melanoma has improved markedly over the last several years with the advent of more targeted therapies. Unfortunately, complex compensation mechanisms, such as those of the mitogen-activated protein kinase (MAPK) pathway, have limited the clinical benefit of these treatments. Recently, a better understanding of melanoma resistance mechanisms has given way to intelligently designed multidrug regimes. Herein, we review the extensive pathways of BRAF inhibitor (vemurafenib and dabrafenib) resistance. We also review the advantages of dual therapy, including the addition of an MEK inhibitor (cobimetinib or trametinib), which has proven to increase progression-free survival when compared to BRAF inhibitor monotherapy. Finally, this review touches on future treatment strategies that are being developed for advanced melanoma, including the possibility of triple therapy with immune checkpoint inhibitors and the work on optimizing sequential therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 97 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 18 | 19% |
| Student > Master | 18 | 19% |
| Student > Bachelor | 13 | 13% |
| Researcher | 12 | 12% |
| Student > Doctoral Student | 9 | 9% |
| Other | 13 | 13% |
| Unknown | 14 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 23 | 24% |
| Biochemistry, Genetics and Molecular Biology | 19 | 20% |
| Medicine and Dentistry | 18 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Chemistry | 3 | 3% |
| Other | 10 | 10% |
| Unknown | 19 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2022.
All research outputs
#7,360,571
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#479
of 2,283 outputs
Outputs of similar age
#104,287
of 397,846 outputs
Outputs of similar age from Drug Design, Development and Therapy
#20
of 94 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,846 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.